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Abstract 
TRANSCRIPTOMIC PROFILING OF VASCULAR ENDOTHELIAL GROWTH 
FACTOR-INDUCED SIGNATURE GENES IN HUMAN CERVICAL EPITHELIAL 
CELLS  
 
MacKinsey Diane Johnson 
B.S., University of North Carolina at Chapel Hill 
Chairperson:  Chishimba Nathan Mowa, Ph.D. 
 
Cervical epithelia cells play central roles in cervical remodeling (CR) during 
pregnancy and cervical events during the menstrual cycle, including mounting physical and 
immunological barriers, proliferation and differentiation, maintenance of fluid balance and 
likely in withstanding the mechanical force exerted by the growing fetus prior to term. We 
have previously characterized the cellular localization of vascular endothelial growth factor 
(VEGF), its receptor and signaling molecules in the cervix of rodents, its profile over the 
course of pregnancy and immediately after birth, as well as characterized its genome- and 
proteome-wide signature genes/proteins. These earlier studies reveal that VEGF and its 
associated molecules largely target and are localized in the cervical epithelial cells. For this 
reason, in the present study, we attempt to decipher the specific roles of VEGF in Human 
cervical epithelial cells by delineating VEGF signature genes using RNA sequencing in order 
to characterize the specific biological effects of VEGF in these cells.  
 Specifically, following optimization of dosage and incubation time, Human cervical 
epithelial cells were treated with either vehicle only (culture media, i.e., negative control) or 
 v 
with 50 ng of exogenous VEGF protein (i.e., treatment group) using an in vitro model. 
Following treatment, cells were harvested, total RNA extracted, followed by RNA 
sequencing, which was verified using real-time PCR analyses of selected genes. Out of a 
total 25,000 genes that were screened, 162 genes were found to be differentially expressed in 
Human cervical epithelial cells, of which 12 genes were found to be statistically significantly 
differentially expressed. The differentially expressed genes (162) were categorized by 
biological function, which included 1) proliferation, 2) immune response, 3) structure/matrix, 
4) mitochondrial function, 5) cell adhesion/communication, 6) pseudogenes, 7) non-coding 
RNA, 8) miscellaneous genes and 9) uncharacterized genes. We conclude that VEGF plays a 
key role in CR by altering the expression of genes that regulate proliferation, immune 
response, energy metabolism and cell structure, biological processes that are essential to CR.  
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 1 
Chapter One: Introduction 
 
 Preterm birth (PTB) has a significant impact on babies and their families, as well as 
the national healthcare system. PTB is considered birth before 37 weeks of pregnancy and 
the leading cause of death in children 5 years old or younger world-wide (Blencowe et al. 
2013). Approximately 15 million babies are born premature every year, and of these about 1 
million die from PTB complications annually (Blencowe et al. 2013, WHO 2018). 
Furthermore, on average the cost associated with preterm birth is $55,000 for the first year of 
the baby’s life compared to approximately $5,000 for a healthy, full-term baby in the first 
year (March of Dimes, 2014). These costs may, in part, be due to the fact that preterm infants 
stay an average of 13 days in the hospital compared to a fetus carried to term whose average 
hospital stay is only 1.5 days (Purisch & Gyamfi-Bannerman, 2017). Also, fetuses born 
preterm are at a higher risk for death or health complications, including, but not limited to, 
breathing problems, feeding difficulties, cerebral palsy, developmental delays, vision and 
hearing problems (CDC 2018). Currently, PTB has an estimated annual health care cost of 
$31 billion USD per year in the USA (Phibbs & Schmitt 2006, Caughey et al. 2016).  
Preterm birth is primarily associated with aberrations in the uterus and cervix and can 
be categorized in 3 ways: spontaneous labor, preterm premature rupture of membranes 
(PPROM), or labor induction for maternal or fetal indications (Goldenberg et al. 2008). The 
specific causes of preterm labor are complex and multifactorial and include: infection, 
inflammation, vascular disease, pre-eclampsia or eclampsia, intrauterine growth restriction 
and aberrations in cervical remodeling (CR) (Goldenberg et al. 2008).  
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 Of particular interest to the present study is the role that CR plays in the induction of 
PTB. CR is a progressive process characterized by structural and biochemical alterations that 
take place in the cervix over the course of pregnancy and immediately after (Vink & 
Feltovich, 2016). It is divided into four overlapping phases: softening, ripening, dilation, and 
repair (Vink & Feltovich, 2016). Cervical softening is characterized by collagen 
reorganization, growth, increased vascularization and edema (Word et al. 2007). Cervical 
ripening generally entails the period prior to uterine contractions and is characterized by an 
increase in abundance of proteoglycan, glycosaminoglycan, collagen synthesis, and an 
increase in cell proliferation (Lee et al. 2005, Word et al. 2007). Cervical dilation occurs 
during active labor and is characterized by the presence of leukocytes and release of 
proteases and collagenases into the extracellular matrix (Word et al. 2007). The final phase 
of cervical remodeling is termed repair and involves a decrease in inflammation, tissue 
dehydration, and re-organization of the structural integrity of the cervical tissue (Word et al. 
2007). Cervical repair occurs immediately after parturition (Word et al. 2007). Of particular 
interest to the present study is the ripening phase of CR when cervical growth and 
proliferation largely occur (Mahendroo et al. 1999, Read et al. 2007, Ruscheinsky et al. 
2008, McGee et al. 2017). The growth of cervical tissue during this phase (cervical ripening) 
is crucial for the cervix to withstand intrauterine pressure and gravity exerted by the growing 
fetus (Myers et al. 2015). Furthermore, cervical epithelial cells also undergo cellular 
differentiation, which is essential for performing its varied roles at different points of the 
menstrual cycle and pregnancy, such as maintaining the immunological and permeability 
barrier, as discussed later (Timmons et al. 2007).  
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Understanding the physical and physiological complexity of the cervix is essential in 
the study of CR. Structurally, the cervix is a barrel-shaped structure located between the 
vagina and the uterus in the female reproductive tract, and is divided into two functionally 
distinct portions, namely the endocervix and ectocervix. These two cervical divisions 
(endocervix and ectocervix) are connected by a squamo-columnar junction (SCJ) or 
transformation zone (TZ), which is a narrow and contiguous junction comprised of 
metaplastic squamous cells derived from stem cells of the endocervix (Vassilakos et al. 2017, 
Deng et al. 2018). Cervical tissue is comprised of a variety of cell types (Feltovich & 
Carlson, 2017), which include smooth muscle, fibroblasts, vascular, immune and epithelial 
cells, which are embedded in the extracellular matrix (ECM). The ECM itself is comprised of 
proteins and proteoglycans, which contribute to the mechanical properties of the cervix 
(Feltovich & Carlson, 2017). The present study focuses on cervical epithelial cells as they 
play the central role in most of the biological processes that occur during CR, such as the 
maintenance of fluid balance, regulation of paracellular transport of solutes, mounting a 
protective and immunological barrier, acting as an “endocrine” gland, and differentiation 
(Mowa et al. 2008, Donnelly et al. 2013). Cervical epithelial cells also play a critical role in 
withstanding the gravitational pressure exerted by the growing fetus and maintaining the 
structural integrity of the cervix throughout cervical remodeling. Specifically, cervical 
epithelial cells provide immunological barrier defense via expression of toll-like receptors 
(TLRs), secretion of antimicrobials, cytokines, chemokines, and mucus (Mahendroo 2017, 
Xu et al. 2018).   
Not only do cervical epithelial cells provide an immunological barrier, but also 
mounts a structural barrier directly by the cells themselves and intercellular junctions 
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(Reviewed by Barrios de Tomasi et al. 2019). Cervical epithelial cells are held together by 
intercellular junctions, which also regulate paracellular transportation and intercellular 
communication (Wira et al. 2005, Anton et al. 2017). One such junction located between 
cervical epithelial cells are tight junctions, which enable the epithelia to establish a physical 
barrier against pathogens as well as polarize the cells (Wira et al. 2014, Wessels et al. 2018). 
Estrogen regulates the expression and activation (via phosphorylation) of key intercellular 
junction proteins, such as occludin and claudin (Wira et al. 2015). Induction of occludin 
expression by estrogen can lead to short-term decrease in trans-epithelial resistance and 
subsequently in the reduction of the integrity of the physical barrier (Gorodeski 2007).   
Our recent studies have also suggested that cervical epithelial cells are likely involved 
in withstanding the pressure of the growing fetus since they are the major source of 
mechano-sensitive signaling molecules during CR (Gordon & Mowa 2019). In part, the 
cervical epithelial cells withstand the gravitational force exerted by the growing fetus by 
proliferating and perhaps expressing regulatory signals that influence other cell types in the 
cervix, such as fibroblasts. It is well known that cervical epithelial cells undergo extensive 
proliferation and differentiation throughout pregnancy and CR. This cellular proliferation 
accounts for 50% of the entire growth of the cervical tissue in gestation (Nallasamy & 
Mahendroo, 2017). Specifically, epithelial cell proliferation is most pronounced during 
ripening of CR (Mahendroo et al. 1999, Mowa et al. 2008). In the rat model, increase in 
cervical wet weight is partially attributed to accumulation of new cells (proliferation) (Burger 
& Sherwood 1998). Lee et al. (2005) have shown that relaxin is one of the regulators of 
epithelial cell proliferation during cervical ripening and the second half of the rat pregnancy. 
The growth in cervical epithelial cell increases the circumference of the cervical lumen and 
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thus the overall enlargement of the cervix (Lee et al. 2005), a process that is crucial for 
preparation of parturition. Furthermore, cervical epithelial proliferation is associated with 
increased mucus production, which provides immunological and mechanical protection, as 
well as anti-microbial function (Cunningham 2010). In the present study, we are specifically 
interested in investigating genome-wide gene expression of human cervical epithelial cell in 
vitro and their associated biological function. Based on our previous studies, it is likely that 
disruption of these biological functions in this cell type could impact CR and pregnancy and 
may likely lead to obstetric complications, including preterm labor. Therefore, we will also 
evaluate how these biological functions influence CR.  
There are several regulatory factors that influence cervical epithelial cell proliferation 
during CR and they include estrogen, relaxin, and hyaluronan (Goldsmith et al. 1995, 
Lenhart et al. 2001, Word et al. 2007, Mahendroo 2017). Our lab has recently shown that 
vascular endothelial growth factor (VEGF) can also induce cervical epithelial cell 
proliferation (Mowa et al. 2008) and identified the genome-wide signature genes regulated 
by VEGF in the various cells of rat cervix during pregnancy. Because of the fundamental role 
of cervical epithelial cells in CR, we use isolated Human cervical epithelial cells in culture to 
characterize the genome-wide effect of VEGF on these cells.  
VEGF is a member of a large family of growth factors that includes four isoforms of 
VEGF as well as placental growth factor (PIGF) (Conn et al. 1990, Tischer et al. 1991, Park 
et al. 1994, Shima et al. 1996, Ferrara & Davis-Smyth 1997). The isoforms include VEGF-A, 
-B, -C, -D, -E and PIGF. VEGF-A is the predominant and most studied isoform (Dulak et al. 
2000, Zachary & Gliki 2001) and can be divided into several splice variants by the number of 
amino acids after signal sequence cleavage, namely 121, 165, 189 and 206 (Mueller et al. 
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2000). VEGFA-165 variant has been shown to be the most potent and abundant in humans 
(Zachary & Gliki 2001). There are three receptors known to mediate the biological properties 
of VEGF and they are: 1) fms-like tyrosine kinase-1 (flt-1) or VEGF receptor 1, 2) kinase 
domain receptor (KDR) or VEGF receptor 2, and 3) fms-related tyrosine kinase 4 (FLT4) or 
VEGF receptor 3 (de Vries et al. 1992, Mustonen & Alitalo 1995, Shibuya 1995, Ferrara & 
Davis-Smyth 1997, Shibuya et al. 1999). However, KDR and flt-1 are considered the 
primary receptors for vascular vessels, while FLT4 mainly mediates VEGF’s effects in 
lymph vessels (Shibuya et al. 1999). VEGF is known to be a regulator of physiological and 
pathological angiogenesis. Such physiological processes include embryogenesis, skeletal 
growth and reproductive functions, while pathological processes involving VEGF-mediated 
angiogenesis include tumor formation and intraocular neovascular disorders (Shima et al. 
1995, Ferrara et al. 2003). Previous studies have shown that induction of angiogenesis by 
VEGF is primarily mediated by the signaling molecule, protein kinase B (Six et al. 2002).  
VEGF and its receptors have been found in the cervix of rodents (Mowa et al. 2004, 
Mowa et al. 2008). Previous DNA microarray studies in our lab have shown that blockage of 
production of local endogenous VEGF in the cervix of pregnant rats alters expression of 
approximately 4,200 genes, which are involved in various biological functions, namely cell 
proliferation, cell motility, circulation, tissue remodeling, immune response and heat shock 
protein activity (Mowa et al. 2008). These biological processes are closely associated with 
CR (Nguyen et al. 2012). Subsequent studies from our lab that followed the DNA microarray 
study showed that VEGF promotes cervical epithelial cell proliferation, trans-epithelial 
recruitment of WBC, and folding/edema (Mowa et al. 2008). Based on these earlier studies, 
we have proposed that VEGF’s influence on cervical epithelial events likely play a crucial 
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role in CR because 1) the cervix must grow to ensure the retention of the fetus in utero 
(proliferation), 2) vascular changes such as angiogenesis and vasodilation are necessary to 
ensure adequate supply of oxygen and nutrients to the cervix undergoing CR, and 3) VEGF 
plays a role in mediating a physiological inflammatory-like response in the cervix considered 
one of the hallmarks of CR.  
 Considering the various effects of VEGF on cervical events and the central role of 
cervical epithelial cells in CR, it is critical to profile the genome-wide expression of VEGF-
regulated genes in cervical epithelial cells and categorize their biological functional groups. 
Therefore, the current study aims to delineate the signature genes regulated by VEGF in 
human cervical epithelial cells in an in vitro model.  
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Chapter Two: Experimental Design 
 
Human cervical epithelial cells (CerEpiCells) were cultured in vitro and treated with 
exogenous VEGF, harvested and then analyzed using RNA sequencing, which was then 
verified by real-time PCR analysis.  
 
Cell culture: CerEpiCells used in the present study were purchased from ScienCell Research 
Laboratories (Carlsbad, CA). Firstly, poly-L-lysine-coated T-75 flasks were prepared by 
mixing 10 mL of sterile water with 15 L of poly-L-lysine stock solution [10 mg/mL] 
(ScienCell Research Laboratories, Cat. #0413 Carlsbad, CA), and then placed in a 37C, 5% 
CO2 incubator overnight under sterile conditions, according to the manufacturer’s protocol. 
Complete basal medium (CerEpiCM, ScienCell Research Laboratories, Cat. #7061 Carlsbad, 
CA) was prepared by mixing 5 mL of Cervical Epithelial Cell Growth Supplement 
(CerEpiCGS, ScienCell Research Laboratories, Cat. # 7062 Carlsbad, CA) with 5 mL of 
penicillin/streptomycin solution (P/S, ScienCell Research Laboratories, Cat. # 0503 
Carlsbad, CA), which were then aseptically added to 500 mL CerEpiCM (ScienCell Research 
Laboratories, Cat. #7061 Carlsbad, CA) under sterile conditions, per ScienCell Research 
protocol. After incubation, poly-L-lysine coated T-75 flasks were decontaminated using 70% 
ethanol, added to sterile field, rinsed twice with sterile water, and then 15 mL of complete 
medium was added to each flask. Cells were thawed from cryopreservation media in 37C 
water bath and then added to each T-75 flask at a seeding density of 6,000 cells/cm2. T-75 
flasks containing cells were incubated overnight at 37C and 5% CO2. Culture media were 
replenished the following day to remove residual DMSO. Thereafter, media were changed 
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every three days until the culture reached approximately 70% confluency and following that 
(reaching 70% confluency), media were changed every other day until the culture reached 
90% confluency.  
 
Sub-culturing cells: CerEpiCells were subcultured into new poly-L-lysine T-75 flasks after 
reaching 90% confluency, according to ScienCell Research Laboratories subculturing 
protocol. Prior to use the following solutions were thawed to room temperature: complete 
media, trypsin/EDTA solution (T/E, ScienCell Research Laboratories, Cat. # 0103 Carlsbad, 
CA), T/E neutralization solution (TNS, ScienCell Research Laboratories, Cat. #0113 
Carlsbad, CA), Dulbecco’s Phosphate-Buffered Saline (DPBS) (Ca++- and Mg++- free, 
ScienCell Research Laboratories, Cat. #0303 Carlsbad, CA) and fetal bovine serum (FBS, 
ScienCell Research Laboratories, Cat. #0500 Carlsbad, CA). Complete media were removed 
from cells and cells were then rinsed once with 10 mL DPBS. Following addition of 5 mL of 
DPBS and 5 mL of T/E solution to T-75 flasks containing cells, the flasks were incubated for 
3 to 5 minutes, until cells were completely round in shape. During the incubation, a 50 mL 
conical centrifuge tube with 5 mL FBS (thawed) was prepared. T/E solution from T-75 flask 
was transferred to the 50 mL centrifuge tube containing FBS and the T-75 flask was 
incubated for an additional 1 to 2 minutes. At the end of the incubation, the flask was gently 
tapped to dislodge cells from the surface. Five mL of TNS solution was then added to the T-
75 flask and detached cells were transferred to 50 mL centrifuge tube, followed by a second 
rinse of the flask with 5 mL TNS solution to collect residual cells. Cell harvest was 
considered successful if fewer than 5% of cells remained in the T-75 flask. The 50mL 
centrifuge tube containing harvested cells was then centrifuged at 1,000 rpm for 5 minutes. 
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The supernatant was removed, and cells were resuspended in 5 mL of CerEpiCM. Two 10 
L samples from the resuspended harvested cells were transferred to 1 mL Eppendorf tubes 
for cell count and viability calculations. Ten L of Trypan Blue dye was added to each 
Eppendorf tube and mixed by pipetting and the stained cell suspension was transferred to the 
hematocytometer for cell count. Cells were counted in each quadrant and the average number 
of cells were determined by calculating the count in each 20 L of resuspended cells in the 
Eppendorf tubes. The average cell count was then multiplied by 5,000 (constant), which was 
multiplied by 5 mL to determine cells/mL in the original cell suspension of the 50 mL 
centrifuge tube. Cells were then subcultured into new poly-L-lysine-treated T-75 flasks at a 
seeding density of 6,000 cells/cm2. Cells were maintained as described above until growth 
reached 90% confluency or until treatment with VEGF. 
 
VEGF Dose Optimization: Initial studies were conducted to determine the optimal dosage 
of exogenous VEGF on epithelial cells in culture. After sub-culturing CerEpiCells into 100 
mm petri dishes (VWR, Cat. # 25373-100 Radnor, PA), cells were treated with three 
different dosages of exogenous recombinant human VEGFA-165 protein (Abcam, Cat. # 
Ab9571 Cambridge, MA) once cells had reached 70% confluency. First, 10 g of VEGF 
protein was dissolved in 100 L 0.1M PBS to constitute a stock solution at a concentration of 
100 ng/L, which was then stored at -20C. Three replicates were used for each treatment 
group, as follows: 1) Negative control (NC) – Vehicle (0.1M PBS) only with 0 ng/mL of 
VEGF treatment; 2) VEGF dose-dependent treatments: a) medium, 30 ng/mL and c) high, 50 
ng/mL. Specifically, the negative control group was treated with a mixture of the following: 
0 L of recombinant VEGF protein, 300 L 0.1M PBS and 9.7 mL cervical epithelial cell 
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medium. Cells in the 30 ng/mL treatment group were treated with 3 L of stock recombinant 
VEGF protein [100 ng/L], 297 L 0.1M PBS, and 9.7 mL cervical epithelial cell medium 
and cells in the 50 ng/mL treatment group were treated with 5 L of stock recombinant 
VEGF protein [100 ng/L], 295 L 0.1M PBS, and 9.7 mL cervical epithelial cell medium. 
After treatment with either vehicle only or recombinant VEGF protein, cells were incubated 
for 24 hours at 37C and 5% CO2. After the 24 hour culture, the cells were harvested to 
extract RNA, and real-time PCR was performed on three selected markers of proliferation 
and a VEGF-sensitive gene in order to determine the optimal dose of VEGF (Fig. 1). The 
real-time PCR protocols outlined below and described in our previous publications were 
utilized (Donnelly et al. 2013).  
 
 
Time Optimization for VEGF Incubation: After optimizing the dosage for VEGF, we then 
conducted experiments to determine the optimal time for treating cells with VEGF under 
different dosages.  Recombinant VEGFA-165 protein stock solution was prepared to a stock 
concentration of 10 g/mL. Cells were plated in 100 mm petri dishes (VWR, Cat. 25373-
100) at a seeding density of 6,000 cells/cm2. Experiments with four treatment groups with 3 
replicates each were conducted as follows: 1) Negative control (NC)– NC group with vehicle 
only with no VEGF added, was harvested at 5 hours post treatment, 2) VEGF treatment 
(optimization of incubation time and dose): a) Lower dose, short term: Cells were treated at a 
lower dose of 30 ng/mL of VEGF and then harvested at 5 hours post-treatment, b) High dose, 
short term: Cells were treated at a higher dose of 50 ng/mL of VEGF and harvested at 5 
hours post-treatment, c) High dose, long term: Lastly, cells were treated at a higher dose of 
50 ng/mL of VEGF and then harvested at 7 hours post-treatment. Specifically, in group 1 
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(NC) cells were grown in 15 mL cervical epithelial cell medium and RNA was extracted at 5 
hours. In group 2a– cells treated with VEGF at a concentration of 30 ng/mL were grown in 
15 mL cervical epithelial cell medium to which was added 45 L recombinant VEGFA-165 
[10 g/mL] at time 0 and a booster of VEGF was added at 4 hours, after which cells were 
harvested and RNA was extracted at 5 hours post treatment to compare efficacy of the 
booster dose with VEGFA-165. In group 2b – cells treated with VEGF at a concentration of 
50 ng/mL cells were grown in 15 mL cervical epithelial cell medium to which was added 75 
L recombinant VEGFA-165 [10 g/mL] at time 0 and RNA extracted at 5 hours post-
treatment. In group 2c – cells treated with VEGF at a concentration of 50 ng/mL cells were 
grown in 15 mL cervical epithelial cell medium to which was added 75 L recombinant 
VEGFA-165 [10 g/mL] at time 0, after which cells were harvested and RNA extracted at 7 
hours post-treatment (Fig. 2). Real-time PCR was performed following the protocol outlined 
below and our previous publications, to determine optimal incubation time for treatment of 
cervical epithelial cells in vitro with exogenous recombinant VEGFA-165 protein.  
 
 
RNA Extraction: RNA was extracted from cells using the Qiagen RNeasy Plus Mini Kit 
(Qiagen, Cat. # 74134 and 74136 Germantown, MD) for cell culture, as described below: 
Following the treatments described above, cells were harvested at 90% confluency by: 1) 
first adding six hundred microliters Buffer RLT Plus to the petri dish containing cells; 2) 
cells were then immediately scraped from culture dish, transferred to 1.5 mL Eppendorf tube 
and vortexed for 30 seconds: 3) the homogenized lysate was then transferred to a gDNA 
Eliminator spin column placed in a 2 mL collection tube and centrifuged for 30 seconds at 
10,000 RPM; 4) the column was discarded, and the flow-through was saved; 5) a volume of 
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600 L 70% ethanol was added to the flow-through volume and mixed by pipetting; 6) Seven 
hundred L of flow-through sample were transferred to a RNeasy spin column placed in a 2 
mL collection tube, centrifuged at 10,000 RPM for 15 seconds; 7) the flow-through was then 
discarded, and steps 6 and 7 were repeated with the remainder of the sample; 8) we then 
added 700 L Buffer RW1 to the RNeasy Mini spin column placed in a 2 mL collection tube 
and centrifuged at 10,000 RPM for 15 seconds and discarded the flow-through thereafter; 9) 
Next, 500 L of Buffer RPE was added to RNeasy spin column, centrifuged at 10,000 RPM 
for 2 minutes, and the flow-through was discarded; 10) Finally, RNeasy spin column was 
placed in a new 2 mL collection tube and centrifuged again for 1 minute at 10,000 RPM to 
further dry the membrane and 11) lastly, the RNeasy spin column was placed in a new 1.5 
mL collection tube and 30 L RNase-free water was directly added to the spin column 
membrane and centrifuged at 10,000 RPM for 1 minute to elute the RNA trapped in the 
membrane.  
 
RNA Extraction Quality Analysis – Nanodrop: After RNA extraction, 2 L of the samples 
were placed on ice for spectrophotometry in order to determine the quality and quantity of 
the RNA samples using ThermoScientific Nanodrop 2000 (Waltham, MA), and the rest were 
snap-frozen and stored at -80C. Two L of elution water (RNase-free water) was loaded for 
“blanking” to initialize and standardize the equipment. RNA samples were then analyzed 
using 2 L of each sample. The A260/A280 ratio, A260/A230 ratio, and the concentration of 
RNA (ng/L) was recorded. The sample reader was cleaned using a KimWipe between each 
sample reading. RNase-free water was then added to each RNA sample to bring the final 
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concentration of each sample to 200 ng/L and mixed well by gently pipetting. Samples were 
then stored at -80C until ready for use. 
 
Reverse transcription: After RNA extraction, total RNA was converted into complementary 
DNA (cDNA) using reverse transcription that utilizes the enzyme reverse transcriptase 
(ThermoFisher Scientific, Cat. # 28025013 Waltham, MA). RT master mix was prepared 
according to the manufacturer’s protocol and our previous studies per reaction: a) M-MLV 
Reverse Transcriptase Buffer (ThermoFisher Scientific, Cat. # 18057018 Waltham, MA) – 2 
L /tube, b) MgCl2 (ThermoFisher Scientific, Cat. # AM9530G Waltham, MA) – 2 L /tube, 
c) dNTP (ThermoFisher Scientific, Cat. # 10297018 Waltham, MA) – 2 L/tube, d) RNase 
inhibitor (ThermoFisher Scientific, Cat. # AM2694 Waltham, MA) – 0.5 L/tube, e) RT-
PCR grade water (ThermoFisher Scientific, Cat. # AM9935 Waltham, MA) – 2 L/tube, and 
f) Random Hexamer Primer (ThermoFisher Scientific, Cat. # SO142 Waltham, MA) – 1 
L/tube. Real-time PCR probes used for determining optimal incubation time, VEGF dose 
and CerEpiCell proliferation studies were purchased from AppliedBiosystem (Waltham, 
MA) and included: 1) glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (normalizer), 2) 
minichromosome maintenance complex component 2 (MCM2), 3) proliferating cell nuclear 
antigen (PCNA), 4) marker of proliferation Ki-67 (Ki-67), and 5) interleukin-6 (IL-6). Real-
time PCR was also performed later to verify genomic data obtained from RNA sequencing 
(For details, see below). RT master mix was prepared and placed on ice or stored at -20C. 
One microgram (5 L) of RNA (200 ng/L) from each sample were aliquoted into 0.2 mL 
PCR tubes. Total volume of RNA in these tubes was brought to 9.5 L using RNase-free 
water and mixed gently by pipetting. Tubes were then incubated in a water bath set at 65C 
 15 
for 5 minutes, followed by incubation at room temperature (23C), while 9.5 L RT master 
mix was added to each tube. Next, 1.0 L of Reverse transcriptase was added to each tube, 
except for the DNA negative control tube. Tubes were then loaded into Thermocycler 
(Eppendorf Mastercycler – epGradient, Hamburg, Germany) and ran under the following 
conditions: 25C for 10 minutes, 42C for 2 hours, 95C for 5 minutes and finally 4C, at 
which the sample was left at until retrieved. cDNA was then stored at -20C until used in 
RT-PCR analysis, described below.  
 
Real-time PCR analysis: Gene expression analysis was used to optimize conditions for 
VEGF treatment of CerEpiCells in culture, as well as verify RNA seq results. Specifically, 
initial studies were conducted to optimize experimental conditions, including incubation time 
and VEGF dosage and later for verifying RNA sequencing data. In the initial optimization 
studies, a set of proliferative markers were used for optimization, including MCM-2, Ki-67, 
and PCNA. TaqMan Gene Expression Assays (ThermoFisher Scientific, Waltham, MA), 
which are pre-designed and pre-optimized gene-specific probe sets, were used and DNA 
amplification was performed using the Applied Biosystems real-time PCR machine (ABI 
7300 HT) with the GeneAmp 7300 HT sequence detection system software (Perkin-Elmer 
Corp). The real-time PCR was set up in 96-well plates using a total volume of 25 L per 
well. The reaction components included the following: 1) 1000 ng (5.0 L) of synthesized 
cDNA, 2) 12.5 L 2X Taqman Universal PCR Master Mix, 3) 1.25 L 20X Assays-on-
Demand-Gene Mix (e.g. Ki-67), and 4) 6.25 L real-time PCR-grade RNAse-free water, and 
the program was set as follows: an initial step of 50 C for 2 min and 95 C for 10 min and 
then 40 cycles of 95 C for 15 s and 60 C for 60 s. The relative amount of the amplified 
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genes was calculated from the threshold cycles with the instrument’s software (SDS 2.0), 
according to the manufacturer’s instructions. Relative expression levels of the target genes 
were normalized to the geometric mean of the endogenous control gene, GAPDH. 
 
RNA-sequencing (NGS): Genome-wide experiments were conducted to identify VEGF-
regulated signature genes in Human cervical epithelial cells, in order to have a 
comprehensive picture of VEGF’s role in regulating these cells and its potential role in CR 
during pregnancy. After optimizing VEGF dosage, incubation time and cell culture 
conditions, cells were treated under these optimal conditions and were harvested, and total 
RNA was extracted and quantified. The extracted total RNA samples were then sent to 
Novogene Co., Ltd (Sacramento, CA) for RNA sequencing and bioinformatic analysis. Total 
RNA quantity and quality were assessed using Nanodrop (OD260/OD280). Agarose gel 
electrophoresis and Agilent 2100 (Bioanalyzer, Waldbronn, Germany) were used to assess 
RNA purity, integrity, and potential contamination. The library was then constructed, and 
quality assessed. Messenger RNA (mRNA) was purified from total RNA using poly-T oligo-
attached magnetic beads. The mRNA was then fragmented randomly by addition of 
fragmentation buffer. The strand-specific library was then constructed by synthesizing the 
second strand cDNA using dUTP. Overhangs of purified double-stranded cDNA were 
converted into blunt ends, adenylation of 3’ ends of DNA fragments, and NEBNext Adaptor 
with hairpin loop structure was ligated to prepare for hybridization and then the second 
strand of cDNA was digested by USER enzyme. The final library was then prepared by PCR 
amplification and purification of PCR products by AMPure XP beads. Bioinformatics 
analysis was then performed on raw data (Fig. 3).  
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Reads mapping to the reference genome: Reference genome and gene model annotation 
files were downloaded from genome website browser (NCBI/UCSC/Ensembl) directly 
(Novogene Co., Ltd.). Indexes of the reference genome was built using STAR and paired-end 
clean reads were aligned to the reference genome using STAR (v2.5) (Novogene Co., Ltd.). 
STAR used the method of Maximal Mappable Prefix (MMP) which generates a precise 
mapping result for junction reads (Novogene Co., Ltd.). 
 
Quantification of gene expression level: HTSeq v0.6.1 was used to count the read numbers 
mapped of each gene and then fragments per kilobase of transcript per million mapped reads 
(FPKM) of each gene was calculated based on the length of the gene and reads count mapped 
to this gene. FPKM, Reads Per Kilobase of exon model per Million mapped reads, considers 
the effect of sequencing depth and gene length for the reads count at the same time, and is 
currently the most commonly used method for estimating gene expression levels (Mortazavi 
et al. 2008). 
 
Differential expression analysis: Differential expression analysis between two 
conditions/groups (two biological replicates per condition) was performed using the DESeq2 
R package (2_1.6.3). DESeq2 provide statistical routines for determining differential 
expression in digital gene expression data using a model based on the negative binomial 
distribution. The resulting P-values were adjusted using the Benjamini and Hochberg’s 
approach for controlling the False Discovery Rate (FDR) (Benjamini & Yekutieli 2001). 
Genes with an adjusted P-value <0.1 found by DESeq2 were assigned as significantly 
differentially expressed. 
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RNA sequencing – Statistical Analysis: Downstream analysis was performed using a 
combination of programs including STAR, HTseq, Cufflink and wrapped scripts. Alignments 
were parsed using Tophat program and differential expressions were determined through 
DESeq2/EdgeR. Results that had adjusted p-value of 0.1 were considered statistically 
significant. 
 
Real-time PCR – Statistical Analysis: Data for real-time PCR analyses were analyzed using 
Student's t-test. P values of <0.05 were considered to be statistically significant. 
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Chapter Three: Results 
 
This chapter describes all the data obtained from the present study, including a) the 
preliminary data obtained during optimization experiments, b) RNA sequencing experiments 
and c) verification data of RNA sequencing by real-time PCR analysis.  
 
Data from optimization studies 
Vascular endothelial growth factor (VEGF) upregulates expression of genes associated 
with proliferation in a dose-dependent manner: CerEpiCells were treated with various 
dosages (30 ng/mL and 50 ng/mL) of human recombinant VEGFA-165 for 24 hours and 
gene expression levels were measured using real-time PCR (Fig. 4). Gene probes associated 
with proliferation (MCM-2, Ki-67 and PCNA) were used to determine the optimal dose of 
VEGFA-165 to be 50 ng/mL (Fig. 4). The optimal dose (50 ng/mL) treated for 24 hours 
produced 125%-fold change in MCM-2 expression as compared to cells receiving no 
treatment of VEGFA-165 (NC) (Fig. 4A). The 50 ng dose produced a 110% fold change in 
PCNA expression as compared to the negative control (Fig. 4B). Ki-67 expression was down 
regulated by the 50 ng VEGF dose (Fig. 4C). Gene probe, interleukin-6 (IL-6) was used as a 
positive control to determine efficacy of treatment with VEGFA-165 protein (Fig. 4D) 
(Nguyen et al. 2012). 
Cells were then treated with 50 ng/mL VEGFA-165 for 5 hours or 7 hours to 
determine optimal treatment time (Fig. 2). Cells were also treated with 30 ng/mL VEGFA-
165 at time 0 and 4 hrs, harvested at 5 hours to compare efficacy of repeat dosing with 
VEGFA-165 (Fig. 2). Using real-time PCR and the same gene probes as discussed previously 
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(MCM-2, Ki-67, and PCNA), 7 hours was determined to be the optimal treatment time (Fig. 
5). The optimal dose (50 ng/mL) treated for 7 hours produced 110%-fold change in MCM-2 
expression as compared to cells receiving no treatment of VEGFA-165 (NC) (Fig. 5A). The 
50 ng dose produced a 111% fold change in PCNA expression as compared to the negative 
control (Fig. 5B). Ki-67 expression was the most significantly up regulated gene by 50 ng 
VEGFA-165 treatment, with a 151%-fold change as compared to the negative control (Fig. 
5C). Gene probe, interleukin-6 (IL-6) was used as a positive control again (Fig. 5D) (Nguyen 
et al. 2012).  
 
Data from RNA sequencing experiments 
VEGF alters gene expression of a variety of genes in Human cervical epithelial cells 
associated with different biological themes: When CerEpiCells were treated with 
optimized concentration of VEGF (50 ng/mL) in culture, it differentially altered the 
expression of 162 genes that are associated with a variety of biological functions or 
properties (Fig. 7, Table 1). The 162 genes were categorized into a total of nine biological 
groups, based on their primary biological properties. Genes were identified and described 
using Ensemble genome browser and HUGO Gene Nomenclature Committee (HGNC).  The 
nine biological groups are: 1) proliferation, 2) energy metabolism, 3) structure/matrix, 4) 
immune response, 5) cell adhesion/cell-cell communication, 6) non-coding RNA, 7) 
pseudogenes, 8) uncharacterized and 9) miscellaneous.  Of these biological themes, the genes 
in only three groups showed significant differential expression, namely those associated with 
proliferation, energy metabolism, and extracellular matrix (Figs. 8, 9, and 10). These three 
biological groups had a total of twelve genes whose expression were found to be statistically 
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significant with p-adjusted value (Padj) < 0.1. Data was analyzed and discussed below based 
on p-adjusted value of 0.1. Out of the twelve genes, 1) Seven genes in CerEpiCells were 
found to be up-regulated by VEGFA-165 with fold changes ranging between 0.33 and 0.39 
[Neural precursor cell expressed developmentally down-regulated protein 8 (NEDD8), FAU 
ubiquitin like and ribosomal protein S30 fusion (FAU), metastasis associated lung 
adenocarcinoma (MALAT1), mitochondrially encoded ATP synthase 6 pseudogene 1 
(MTATP6P1), mitochondrially encoded cytochrome c oxidase III (MT-CO3), 
mitochondrially encoded ATP synthase 6 (MT-ATP6), mitochondrially encoded cytochrome 
c oxidase subunit 2 (MT-CO2)] (Fig. 8 and 9); and 2) Five genes were found to be down-
regulated with fold changes between -0.44 and -0.39 [solute carrier family 6 member 14 
(SLC6A14), collagen type 1 alpha 1 chain (COL1A1), C-X-C motif chemokine ligand 14 
(CXCL14), sestrin 3 (SESN3), keratin 4 (KRT4)] (Figs. 8 and 10).  
 
VEGF differentially alters expression of genes associated with proliferation in Human 
cervical epithelial cells: Exogenous VEGFA-165 was found to differentially alter the 
expression of a total of nineteen genes associated with proliferation, out of the 162 genes that 
were differentially expressed, i.e., proliferation genes constituted 12% of the total altered 
genes (Table 2). Of the nineteen proliferation associated genes, the majority of these genes 
(9, i.e., about 47%) were down-regulated, with the rest (10, i.e., 53%) up-regulated (Table 2). 
Further, out of nineteen genes, only six genes were significantly differentially expressed, of 
which half (NEDD8, FAU, and MALAT1) were up-regulated (NEDD8, FAU, and MALAT1) 
and the remaining half were down regulated (CXLC14, SESN3, SLC6A14) (Padj < 0.1) when 
CerEpiCells were treated with VEGFA-165 (Table 2, Fig. 8). The log2 fold changes for 
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NEDD8, FAU, and MALAT1 were 0.33, 0.35, 0.33, respectively and that of CXCL14, SESN3 
and SLC6A14 were -0.42, -0.42, -0.44, respectively (Table 2). To verify these RNA seq (next 
generation sequence) data showing VEGF’s effects on the expression pattern of proliferative 
genes, real-time PCR was used on the following select genes (SESN3 & MT-ATP6) (Figs. 11 
and 12). 
 
VEGF differentially alters expression of genes associated with energy metabolism and 
Matrix in Human cervical epithelial cells: As stated previously, among the biological 
groups with genes that were significantly expressed included those associated with 
extracellular matrix, mitochondrial function and proliferation. Of the 162 differentially 
expressed genes, VEGF was found to regulate seven genes categorized as energy 
metabolism. Four of the twelve significantly differentially expressed genes were categorized 
as energy metabolism and were significantly up-regulated in cells treated with VEGFA-165 
as compared to the negative control. These included MTATP6P1, MT-CO3, MT-ATP6, MT-
CO2 (Fig. 9). Specifically, the fold change of MTATP6P1, MT-CO3, MT-ATP6, MT-CO2 
were 0.39, 0.34, 0.39, 0.39, respectively. Two genes associated with extracellular matrix 
were significantly down-regulated (COL1A, KRT4) in cells treated with VEGF as compared 
to the negative control (Fig. 10). The fold changes for these two genes were -0.41 (COL1A1) 
and -0.39 (KRT4).  
 
Verification of RNA sequencing data by real-time PCR analysis  
RNA-seq results of select genes (SESN3 & MT-ATP6) were verified using real-time PCR. 
The gene expression using these two gene probes (SESN3 & MT-ATP6) was measured using 
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cells treated with 50ng exogenous VEGF for 7 hours compared to cells receiving no VEGF 
treatment (NC) following the Reverse Transcription protocol as described previously. 
GAPDH was used as a normalizer. Real-time PCR analysis showed that SESN3 is 
significantly down regulated by exogenous VEGF in CerEpiCells, whereas MT-ATP6 is up 
regulated (Fig. 11, p-value < 0.05). These results match RNA-seq data.  
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Chapter Four: Discussion 
Cervical epithelial cells have been shown to play a central role in reproductive events, 
notably cervical remodeling and, consequently, their dysfunction could possibly be 
implicated in PTB (Laurent & Fraser 1992, El Maradny et al. 1997). We have previously 
delineated VEGF-regulated genes and biological functions in the different cell types of rat 
cervix during pregnancy using VEGF inhibitors and DNA microarray (Mowa et al. 2008). 
Specifically, based on these earlier studies, VEGF’s biological effects on all the cervical 
tissue cell types of pregnant rats include proliferation, immune response, tissue remodeling, 
cell motility, circulation, and heat shock protein activity (Mowa et al. 2008). The biological 
themes of some of these DNA microarray data were later confirmed by our most recent 
studies that showed that local administration of exogenous recombinant VEGF in mouse 
cervix induces marked proliferation and growth of epithelial cells. We also demonstrated 
increased intercellular permeability and immune cell infiltration into cervical lumen 
(Donnelly et al. 2013). Therefore, the present study focused on teasing out the specific 
VEGF-regulated signature genes in human cervical epithelial in vitro using RNA seq. Of the 
total 25,000 + genes that were examined in human cervical epithelial cells, 162 genes were 
found to be differentially expressed (Fig. 7). These 162 genes were then categorized into nine 
different biological groups, namely: 1) proliferation, 2) immune response, 3) 
structure/matrix, 4) mitochondrial function, 5) cell adhesion/communication, 6) pseudogenes, 
7) non-coding RNA, 8) miscellaneous genes and 9) uncharacterized genes (Table 1), 
consistent with earlier findings from rodent studies. Real-time PCR was used to verify RNA 
seq data. Finally, out of the total 162 genes that were differentially regulated by VEGFA-
165, only twelve were found to be statistically significantly expressed based on p-adj value < 
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0.1. The twelve genes were further characterized into three functional biological groups, 
namely proliferation, energy metabolism and matrix (Figs. 8, 9, and 10). It is important to 
note that some genes are associated with multiple functions, and, therefore, belong to more 
than one category. 
Consistent with findings of our earlier rodent studies, the present study found that 
VEGF altered the gene expression of proliferative genes in human cervical epithelial cells the 
most (19/162) and out of the 12 genes that were significantly differentially expressed, six 
belonged to proliferative genes (CXCL14, SESN3, SLC6A14, NEDD8, FAU, MALAT1). 
However, there was a difference in the specific types of proliferative genes involved and the 
pattern of expression, likely reflecting species differences as well as the type of models used, 
i.e., in vitro (Human) versus in vivo (Rodents). While VEGF mostly promoted expression of 
proliferation genes in human cervical epithelial cells, it down regulated expression of some 
of the proliferation genes and those that inhibited proliferation. For example, SESN3, which 
inhibits proliferation, was down regulated by VEGF. Also, as discussed earlier, some of the 
genes associated with proliferation also exerted other biological effects, such as CXCL14, a 
chemokine primarily involved in immune response but also inhibits proliferation of breast 
cancer and endothelial cells (Shellenberger et al. 2004, Noonan et al. 2008, Gu et al. 2012).  
VEGF was found to down regulate expression of CXCL14 in human cervical 
epithelial cells in the present study (Fig. 8). CXCL14, which has previously been shown to be 
localized in the cervix (Frederick et al. 2000, Lu et al. 2016), encodes for a homeostatic 
chemokine that belongs to a superfamily of small chemotactic cytokines (Hernández-Ruiz & 
Zlotnik 2017). CXCL14 regulates multiple functions, including cell survival, angiogenesis, 
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tumor cell proliferation and immune response (Rollins 2006, Zlotnik 2006). Of interest to the 
present study, CXCL14 has significant expression in mucosa with three other chemokines 
(CCL28, CCL25, CXCL17). These four chemokines also have broad anti-microbial activity, 
suggesting their potential to influence the composition of the mucosal microbiome. 
Specifically, CXCL14 exhibits antimicrobial activity against Gram-negative Escherichia coli 
(E. coli), Gram- positive Staphylococci species, Propionibacteria, Pseudomonas aeruginosa, 
Streptococcus species, and the yeast C. albican (Dai et al. 2015). CXCL14 could, therefore 
play a relevant role in local cervical immune surveillance (Maerki et al. 2009, Dai et al. 
2015). It is however not clear for now why VEGF down regulates CXCL14 since we have 
previously shown that VEGF induced immune response in pregnant rats and specifically 
promoted immune recruitment into cervical lumen of non-pregnant mice cervix (Donnelly et 
al. 2013). However, we did not specifically investigate the immune cell types that were 
recruited by VEGF. Since CXCL14 does not recruit all immune cell types (B-cells, 
monocytes, neutrophils, and dendritic cells) (Cao et al. 2000, Sleeman et al. 2000, Kurth et 
al. 2001), it is likely that it (CXCL14) does not mediate VEGF-induced immune recruitment 
in the cervix (Donnelly et al. 2013, Stanley et al. 2018). Perhaps another reason VEGF 
diminished levels of CXCL14 in cervical epithelial is because CXCL14 appears to also 
oppose another key role of VEGF, namely angiogenesis. CXCL14 enhances maturation of 
dendritic cell (DC) (Shellenberger et al. 2004, Noonan et al. 2008), which (maturation of 
DC) has been found to be inhibited by VEGF (Sozzanni et al. 2007). We have previously 
shown that VEGF promotes angiogenesis in the cervix during pregnancy and proposed that 
this biological property of VEGF plays a critical role in CR (Mowa et al. 2004). CXCL14 has 
also been found to inhibit proliferation in breast cancer cells in vitro (Gu et al. 2012). Taken 
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together, we reason that VEGF down-regulates CXCL14 in an effort to promote cervical 
epithelial cellular proliferation, which CXCL14 likely inhibits. The present findings confirm 
CXCL14’s role in mucosa and that VEGF may attenuate CXCL14’s immune and anti-
proliferative effects in cervical mucosa. However, the exact role of CXCL14 in cervical 
events and its mode of interaction with VEGF requires more study. Future studies should 
investigate CXCL14’s specific role in the immune response found in cervical mucosa as well 
as determine the specific VEGF-receptor and subsequent signaling pathways used to alter 
expression of CXCL14 by VEGF.  
SESN3 was also found to be down-regulated by the present study in human cervical 
epithelial cells after treatment with recombinant VEGFA-165. SESN3 belongs to the sestrin 
family, which is a highly conserved family of stress-responsive proteins whose expression is 
primarily regulated via p53 signaling pathway (SESN1 and SESN2) (Nogueira et al. 2008, 
Budanov et al. 2010). Different from the other two sestrin molecules, SESN3 is up-regulated 
by forkhead box transcription factor belonging to O-subclass (FoxO), a downstream effector 
molecule from Akt (Nogueira et al. 2008). FoxO activity is negatively regulated by Ras 
signaling through the AKT/protein kinase B (PKB) and ERK protein kinases (Yang & Hung 
2009). Therefore, activation of the Ras signaling pathway results in down-regulation of 
SESN3 (Kopnin et al. 2007, Budanov et al. 2010).  Although the underlying mechanism that 
VEGF may use to down regulate levels of SESN3 in human cervical epithelial cells as 
revealed by the present study are for now unclear, it is interesting to note that the molecules 
of the Ras pathway (AKT/protein kinase B (PKB) and ERK protein kinases), which down 
regulate SESN3, are established key signaling molecules used by VEGF and cancer cell 
proliferation and endothelial cells (Zhong et al. 2000, Fang et al. 2007, Claesson-Welsh 
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2016). It is possible that this negative regulation of SESN3 by VEGF may occur due to the 
down regulation of FoxO activity by Ras activation (Yang & Hung 2009). SESN3 is 
positively regulated by FoxO transcription factors (Nogueira et al. 2008), therefore when Ras 
signaling is activated by VEGF (Cross & Claesson-Welsh 2001), it in turn likely down-
regulates FoxO signaling and thus SESN3. The down regulation of SESN3 was confirmed by 
RT-PCR analysis, which showed SESN3 expression is significantly (p-value < 0.05) less in 
VEGF treated cells as compared to SESN3 expression in NC.  
The third gene down-regulated by VEGF (Fig. 8), SLC6A14, is a transporter of 
multiple amino acids and therefore plays a critical role in the maintenance of amino acid 
nutrition (Babu et al. 2015). Of interest to the present study, among the amino acids 
SLC6A14 transports is arginine, a crucial ingredient for nitric oxide (NO) production (Gupta 
et al. 2006), an inducer of VEGF expression. NO also enhances the activity of hypoxia 
inducible factor (HIF), one of the most potent transcription factor of VEGF (Kimura & 
Esumi 2003). Based on these facts, one would have therefore thought that VEGF would up 
regulate SLC6A14 so that there would be more raw material for NO, arginine, transported 
into cervical epithelial cells to promote activity of HIF, which would then up regulate VEGF 
to stimulate epithelial proliferation. This speculation is in line with the fact that blockage of 
SLC6A14 inhibits amino acid transport and subsequently cancer growth (Gupta et al. 2006). 
It appears that SLC6A14 may not play a significant role in proliferation of cells under 
physiological conditions since its level of expression is normally very low, including in 
cervical epithelial cells (Gupta et al. 2006). The results shown by Gupta et al. (2006) match 
the findings of the present study. More studies are required to tease out the intricate 
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relationship between SLC6A14, NO, HIF and VEGF in cervical epithelial cells under 
different physiological conditions and how this relates to CR and preterm birth.  
We also found that VEGF upregulate levels of NEDD8 in human cervical epithelial 
cells in vitro by the present study (Fig. 8). NEDD8 is a regulatory protein involved in a range 
of fundamentally key biological activities in cell growth, viability and development (Mori et 
al. 2005, Ryu et al. 2011). It exerts its effects by activating a class of scaffold proteins, 
cullin-RING ubiquitin ligases (CRLs) (Ryu et al. 2011), which comprise the largest family of 
E3 enzymes involved in the ubiquitin-proteasome system (UPS) (Duda et al. 2008, Deshais 
2017). The UPS uses enzyme-mediated specificity to regulate and degrade specific proteins 
(Varshavsky 2005). Each type of CRL associates with different combinations of proteins to 
form a multiprotein complex composed of an adaptor protein, substrate receptor and the 
target substrate (Scott et al. 2016). It is most likely that the NEDD8 up regulated by VEGF in 
the present study activates CRL-2, whose adaptor protein and substrate receptors are EI-C 
and SOCS-box, respectively, and are associated with the Von Hippel-Lindau protein (VHL). 
The target protein of this multiprotein complex is HIF (Kershaw & Babon 2015), 
a transcription factor that regulates expression of more than 100 genes, including cell 
proliferation, apoptosis, angiogenesis, glycolysis, iron metabolism and others, under low 
oxygen conditions as reviewed by Schofield and Ratcliff (2004). Under hypoxic conditions 
HIF-α is not degraded (Schofield & Ratcliffe 2004, Ryu et al. 2011). However, when oxygen 
levels are adequate the 402 and 564 proline residues of HIF- are hydroxylated by prolyl 
hydroxylase (PHD 2/3), which then becomes detectable to VHL and is subsequently 
presented for degradation by the 26S proteasome (Schofield & Ratcliffe 2004). In summary, 
when VEGF up regulates NEDD8 in human cervical epithelial cells, as revealed by the 
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present study, it leads to degradation of its transcription factor, HIF-, which in turn will 
mitigate VEGF expression and its downstream effects. Therefore, we propose that VEGF in 
cervical epithelial cells appear to exert a negative feedback effect on HIF- in vitro. It is not 
clear whether this is the same under in vivo conditions or is not true for cervical epithelia 
cells since we have shown previously that levels of VEGF increase over the course of 
pregnancy and decrease after birth in rodents (Mowa et al. 2004, Donnelly et al. 2013, 
Stanley et al. 2018). More studies need to be conducted to verify these hypotheses.  
FAU was also up-regulated by VEGF (Fig. 8); however, little is known about their 
exact interactions. FAU is considered a house-keeping gene that regulates apoptosis of 
epithelial and T-cell lines and also possesses immunomodulatory and anti-microbial activities 
(Pickard 2012). FAU expression in normal tissues is largely invariant, however its expression 
has been found to be down-regulated in a number of human cancers (Pickard 2012). The up-
regulation of FAU’s pro-apoptotic function is in contrast to the overall function of VEGF 
(angiogenesis and proliferation). Perhaps overexpression of VEGF indicates an aberrant 
tissue growth and may trigger FAU expression. However, further research is required to fully 
understand VEGF – FAU interactions.  
The sixth gene characterized as having proliferative function is MALAT1, which is 
also up-regulated by VEGF (Fig. 8). MALAT1 encodes a highly conserved nuclear non-
coding RNA that promotes vascular formation and plays an important role in tumor-driven 
angiogenesis (Gutschner et al. 2012). Similar to the up-regulation of MALAT1 induced by 
VEGF in cervical epithelial cells, Li et al. (2017) found a positive correlation between 
MALAT1 and VEGF expression in both umbilical cord cells and mesenchymal stem cells. 
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More specifically, VEGF mRNA and protein expression were increased after overexpressing 
MALAT1 in cells derived from patients with pre-eclampsia (Li et al. 2017), suggesting a 
reciprocal relationship between VEGF and MALAT1. Interestingly, pre-eclampsia is 
associated with maternal complement activation (Derzsy et al. 2010), and Gonzalez et al. 
(2011) has shown that complement activation in the mouse model is also linked to CR and 
pre-term birth, which indicates VEGF and MALAT1 could play a crucial role in CR.  
Of the twelve significantly differentially expressed genes, four genes associated with 
mitochondrial function and ATP synthesis were found to be significantly up-regulated by 
VEGF in human cervical epithelial cells in the present study (MT-ATP6P1, MT-CO3, MT-
ATP6, MT-CO2) (Fig. 9). MT-ATP6P1 is a pseudogene or a segment of DNA related to the 
original gene (MT-ATP6) which may or may not have lost some functionality relative to the 
complete gene (Tutar 2012). Tutar (2012) reports that pseudogenes can also perform 
regulatory functions. MT-ATP6P1 has been shown to encode for accessory proteins of 
vacuolar (H+) – ATPases (V-ATPases) (Forgac 2007). V-ATPases combine energy from 
ATP hydrolysis to proton transport across membranes of eukaryotic cells (Forgac 2007). In a 
study by Pareja et al. (2018) in human embryonic cells when loss of function mutation occurs 
in MT-ATP6P1 it results in decreased V-ATPase activity as well as decreased endosomal 
acidification. Endosomal acidification is also important for homeostasis and maturation of 
endosomes which are transport vesicles found in the cytoplasm (Hu et al. 2015). MT-ATP6 
encodes a subunit of ATP-synthase, the final step in oxidative phosphorylation where ATP is 
produced (Genetics Home Reference – MTATP6, Weber & Senior 2004). Real-time PCR 
analysis showed that VEGF up regulates MT-ATP6 as compared to NC, however the 
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expression levels were not significantly different. Little is known about the interaction of 
MT-ATP6P1 or MT-ATP6 specifically in cervical epithelial cells or in relation to VEGF.  
MT-CO2 and MT-CO3 are closely linked genes which encode for cytochrome C 
oxidase (COX) subunits two and three, respectively (Genetics Home Reference – MTCO2, 
Genetics Home Reference – MT-CO3). Both genes are functionally active in respiratory 
electron transport, ATP synthesis and heat production (Gene Cards). COX is the last enzyme 
in the electron transport chain that powers ATP synthase to produce ATP (Li et al. 2006). No 
studies to date have shown a direct interaction between VEGF and MT-CO2 or MT-CO3 in 
human cervical epithelial cells. In mouse fibroblast cells, Li et al. (2006) found that when 
COX is dysfunctional it leads to compromised mitochondrial membrane potential, decreased 
ATP production, and decreased growth of cells in media; thus, indirectly linking the 
importance of COX in cell growth and proliferation. However, the direct relationship 
between COX and VEGF remains to be elucidated, specifically in cervical epithelial cells.  
The findings of our present study on VEGF’s effect on expression of genes related to 
mitochondrial function are critical as they extend VEGF’s impact on cervical epithelial 
physiology beyond its traditionally established roles to date. They (findings) imply that 
VEGF does not only ensure adequate oxygen perfusion of cervical tissue via angiogenesis, as 
well as proliferation of cervical epithelial cells, but it (VEGF) also stimulates production of 
the energy required to power these energy-dependent processes. Therefore, local dysfunction 
of VEGF synthesis will consequently have much broader implications beyond just disrupting 
angiogenesis; dysfunctional VEGF could potentially threaten to shut down cervical epithelial 
function altogether. Although these findings are the first to be reported in cervical epithelial 
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cells, they are consistent with several earlier studies conducted in endothelial cells from 
different tissues (Guo et al. 2017). For instance, a study by Guo et al. (2017) showed that 
VEGF treatment of human umbilical vein endothelial cells (HUVECs) increases 
mitochondrial oxidative respiration and intracellular ATP levels. According to this study 
(Guo et al. 2017), VEGF promoted mitochondrial function in HUVECs through the 
mammalian target of rapamycin (mTOR) signaling pathway. Mitochondrial function can also 
be induced upstream of VEGF by hypoxia and HIF. Specifically, hypoxia induces 
mitochondrial generation of reactive oxygen species (mROS) (Chandel et al. 1998). In turn, 
mROS will then stabilize VEGF’s transcription factor, HIF subunits (Chandel et al. 2000, 
Kimura & Esumi 2003), by blocking the enzyme, propyl hydroxylase, that tags HIF for VHL 
to trigger ubiquitination and subsequent degradation (Ryu et al. 2011). Of particular interest 
to the present study, others have also shown that mitochondrial ROS are crucial to the 
regulation of cell proliferation (Sena & Chandel 2012). It is therefore likely that unlike the 
NEDD8 relationship discussed earlier, a positive feedback loop between VEGF and HIF (and 
perhaps cervical epithelial proliferation) exists; i.e. VEGF up regulates expression of 
mitochondrial genes, which then promotes production of ATP to power cervical epithelial 
events such as proliferation and also generates mROS leading to the stability of HIF. HIF in 
turn up regulates expression of VEGF which then regulates and powers several cervical 
epithelial events. In addition, a review by Hamanaka and Chandel (2010) states that 
mitochondrial generation of ROS is also necessary for other essential biological signaling 
events, such as transcription, calcium storage, and energy storage. Other studies have also 
shown that VEGF induces mitochondrial biogenesis (Wright et al. 2008). More mechanistic 
studies need to be conducted in cervical epithelial cells to test these speculations. Also, 
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because of the importance of energy metabolism to cell survival, there are likely multiple and 
redundant regulatory factors involved in cervical epithelial cell energy metabolism. 
Two genes (KRT4, COL1A1) classified as extracellular matrix genes were both down-
regulated in cervical epithelial cells treated with VEGF (Fig. 10). Consistent with earlier 
findings from our lab’s in vivo model with rodents, VEGF alters the gene expression of some 
matrix genes, mainly COL1A1. On the other hand, while KRT4 was found to be altered by 
VEGF in vitro in the current study, the microarray data from our previous studies did not 
show altered expression of this gene in vivo using the rodent model. The cytoskeleton 
(KRT4) plays a crucial role in cell cycle progression, cell death, and differentiation (Ahn et 
al. 2004) and is therefore a critical structure to consider in regard to cellular growth and 
proliferation.  
COL1A1 is a gene which encodes for collagen, a cellular structure protein (Ahn et al. 
2004) and under pathological conditions is typically associated with metastasis (Chen et al. 
2003). Furthermore, COL1A1 is concomitantly up-regulated with increased VEGF 
expression in tumors (Calvo et al. 2008). This is in direct contrast to our findings, which 
showed that COL1A1 is down-regulated upon treatment with VEGF (Fig. 10). Perhaps, as 
Chen et al. (2003) suggests, there is a complex and coordinated mechanism of gene 
regulation occurring between the cervical epithelium and the microenvironment (i.e stromal 
cells, fibroblasts, etc.), specifically in cancer progression. Therefore, based on this logic we 
propose that the down-regulation of COL1A1 upon VEGF treatment is due to the lack of 
interaction between cervical epithelial cells and the other cervical cellular type (i.e. stromal 
cells), since we are using an in vitro model of cervical epithelial cells. It is also possible that 
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COL1A1 expression is regulated differently in different cell types (i.e cervical epithelial cells 
versus fibroblasts).  
KRT4 encodes a keratin and plays a protective role from mechanical and non-
mechanical stress in epithelial cell function, which could lead to apoptosis (Coulombe & 
Bishr Omary 2002). While KRT4 is not well characterized in healthy cervical epithelial cells, 
Wong et al. (2006) showed that KRT4 is down-regulated in cervical squamous cell carcinoma 
and while, simultaneously, VEGF is up-regulated. These results are consistent with our 
present findings showing down-regulation of KRT4 by VEGF. VEGF is known to play a 
crucial pathological role in tumor angiogenesis and proliferation (Gaffney et al. 2003). 
Therefore, perhaps VEGF negatively regulates apoptosis of cells via KRT4 in order to induce 
proliferation of cells.  
The sex steroid hormones, estrogen and progesterone, play the central role in female 
reproductive events during menstrual cycle and pregnancy (e.g., CR). Similar to VEGF, 
estradiol promotes epithelial cell proliferation while, in contrast, progesterone inhibits 
proliferation of these cells (Chung 2015, Mehta et al. 2016). Of interest to the present 
findings, multiple studies have demonstrated that estradiol increases levels of VEGF in 
multiple cell types (Cullinan-Bove & Koos 1993, Shifren et al. 1996, Bausero et al. 1998, 
Hyder et al. 2000, Mueller et al. 2000, Soares et al. 2002, Soares et al. 2004) and during CR, 
the two sex steroids (Estrogen and progesterone) regulate most of the genes expressed by the 
epithelial tissue (Andersson et al. 2008, Timmons et al. 2010). In fact, Havelock et al. (2005) 
reports that expression of estrogen- and progesterone-sensitive genes are more pronounced in 
the cervix compared to uterine fundus. Importantly, we have previously demonstrated that 
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VEGF and it’s signaling molecules are present in the cervix of non-pregnant women and up 
regulated over the course of pregnancy as levels of sex steroid hormones increase and sharply 
decrease immediately after birth (Mowa et al. 2004, Donnelly et al. 2013). Furthermore, we 
have shown that exogenous estrogen up regulates expression of VEGF in mice cervix 
(Ohashi et al. 2014) implying that estrogen may either act up stream of VEGF or directly 
regulate the expression of VEGF-regulated genes, revealed in the present study. Also, several 
studies have shown that estrogen alters expression of several of these genes in different 
tissues. Of the twelve differentially expressed genes, nine are sensitive to estrogen. Seven of 
these genes are up-regulated by estrogen in various cell types (CXCL14, SESN3, FAU, 
MALAT1, MT-CO3, COL1A1) (Ivanova et al. 2013, Markiewicz et al. 2013, McCracken & 
Eldridge 2015, Ren et al. 2015, Sjöberg et al. 2016, Klinge 2018), while only one gene is 
down-regulated (KRT4) (Walker et al. 2007). Interestingly and opposite to estrogen 
regulation, NEDD8 was found to be a regulator of ER- expression in breast cancer tissue 
(Jia et al. 2019). There is no information to date on the relationship of estrogen and the 
remaining two genes, MT-ATP6P1 and MT-ATP6. The implications of the present findings to 
CR and their underlying mechanism are currently unclear and thus will require more studies 
in the future. Future studies should determine the interaction and relationship between 
estrogen, VEGF, and the aforementioned genes in cervical epithelial cells.  
In summary, the present study has shown that VEGF induces expression of multiple 
genes in CerEpiCells in vitro (Fig. 12). Particularly, the majority of the genes that VEGF 
induces in CerEpiCells are those associated with proliferation, a biological process which 
plays a crucial role in CR. Collectively, these findings suggest that VEGF plays a key role in 
CR by inducing expression of several genes that regulate three biological functions that are 
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necessary for cervical remodeling to occur normally (cell proliferation, mitochondrial 
function, and cell structure integrity).  
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Figures and Tables 
 
 
Figure 1: Schematic diagram of VEGF dose optimization experiments.  
 
 
 
Figure 2: Schematic diagram of VEGF incubation time optimization experiments. 
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Figure 3: Workflow map of RNA sequencing bioinformatic analysis  
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Figure 4. Human recombinant vascular endothelial growth factor – 165A protein 
(VEGFA-165) upregulates gene expression of genes associated with proliferation in a 
dose-dependent manner. Levels of MCM-2 (A) and PCNA (B) mRNA in Human cervical 
epithelial cells were up-regulated in cells treated with 50 ng/mL VEGFA-165 protein for 24 
hours, as revealed by real-time PCR. Levels of Ki-67 (C) were not significantly increased by 
either 30 ng/mL or 50 ng/mL VEGFA-165 protein. IL-6 probe was used as a positive control 
(D) (n=4).  
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Figure 5. Human recombinant vascular endothelial growth factor protein (VEGFA-
165) upregulates gene expression of genes associated with proliferation. Levels of MCM-
2 (A), PCNA (B), and Ki-67 (C) mRNA in Human cervical epithelial cells were up-regulated 
with cells treated with 50 ng/mL VEGFA-165 protein for 7 hours, as revealed by real-time 
PCR. IL-6 probe was used as a positive control (D) (n=4) 
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Figure 6. Volcano plot shows overall profile of VEGF-induced gene expression in 
human cervical epithelial cells. Of the total genes examined, nine were significantly 
expressed, of which five were up-regulated (red dot) and four were down-regulated (green 
dot) by VEGF (P-adjusted value <0.05; n=3).  
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Figure 7. Heat map illustrating the effect of vascular endothelial growth factor (VEGF) on 
the gene expression profile of Human cervical epithelial cells versus vehicle (Negative 
control group) in culture. 
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Figure 8. Vascular endothelial growth factor (VEGF) differentially alters expression of 
genes associated with proliferation in Human cervical epithelial cells. While VEGF 
significantly upregulates expression of three out of six genes (50%) associated with 
proliferation (NEDD8, FAU, MALAT1), it significantly downregulates the other half 
(CXCL14, SESN3, SLC6A14). P-adjusted value < 0.1, n=3.  
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Figure 9. Vascular endothelial growth factor (VEGF) up regulates expression of genes 
associated with mitochondrial function in Human cervical epithelial cells. VEGF 
significantly upregulates expression of all the four genes associated with energy metabolism 
in human cervical epithelial cells (MTATP6P1, MT-CO3, MT-ATP6, MT-C02). P-adjusted 
value < 0.1, n=3.  
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Figure 10. Vascular endothelial growth factor (VEGF) down regulates expression of 
extracellular matrix genes in Human cervical epithelial cells. VEGF significantly down 
regulates expression of genes associated with extracellular matrix, namely COL1A1 and 
KRT4. P-adjusted value < 0.1, n=3.  
 
 
 
 
 
 
 
 
 
Figure 11. Verification of RNA-seq data by real-time PCR analysis. Treatment of Human 
cervical epithelial cells with VEGF leads to down regulation of SESN3 expression (A) and 
tends to up regulates MT-ATP6 (B), as revealed by RT-qPCR (n=4), *p<0.05. MT-ATP6 not 
statistically significant. 
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Figure 12. Proposed working model showing VEGF-regulated biological processes in 
Human cervical epithelial cells.  
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Table 1. Functional properties of the 162 VEGF-induced signature genes in Human cervical 
epithelial cells.  
 
BIOLOGICAL 
GROUP 
GENE NAME 
LOG2 FOLD 
CHANGE 
PROLIFERATION 
V-MYB Myeloblastosis Viral Oncogene Homolog 
(MYB) 
3.27 
 
Farnesyltransferase CAAX box Beta 
(FNTB) 
6.43 
 
Metastasis Associated Lung Adenocarcinoma Transcript 1 
(MALAT1) 
0.33 
 
R-spondin 4 
(RSPO4) 
6.57 
 
Hect Domain and RLD 2 Pseudogene 10  
(HERC2P10) 
3.14 
 
Casein Kinase 2 Beta Polypeptide 
(CSNK2B) 
1.36 
 
Apolipoprotein B mRNA Editing Enzyme Catalytic 
Polypeptide-like 3A 
(APOBEC3A) 
6.25 
 
Apolipoprotein B mRNA Editing Enzyme Catalytic 
Polypeptide-like 3A 
(FAU) 
0.35 
 
C-type Lectin Domain Family 3 Member A 
(CLEC3A) 
-6.86 
 
STE20-related Kinase Adaptor Alpha 
(STRADA) 
-2.12 
 
Ankyrin Repeat Domain 44 
(ANKRD44) 
-3.58 
 
Solute Carrier Family 6 (amino acid transporter) Member 
14 
(SLC6A14) 
-0.44 
 
Transmembrane Protease Serine 13 
(TMPRSS13) 
-1.67 
 
Short Chain Dehydrogenase/Reductase Fmaily 9C 
Member 7 
(SDR9C7) 
-2.12 
 
Short Chain Dehydrogenase/Reductase Fmaily 9C 
Member 7 
(SESN3) 
-0.42 
 
TP3 Target 5 
(TP53TG5) 
-2.79 
 
 
Sclerostin Domain Containing 1 
(SOSTDC1) 
 
-3.10 
 Chemokine (CXC Motif) Ligand 14 -0.42 
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(CXCL14) 
IMMUNE RESPONSE 
Caspase Recruitment Domain Family Member 17 
(CARD17) 
-6.25 
 RP11-1112J20.2 2.71 
 
Dedicator of Cytokinesis 2 
(DOCK2) 
7.17 
 
Triggering Receptor Expressed on Myeloid Cells-like 2 
(TREML2) 
6.73 
 
CAP-GLY Domain Containing Linker Protein 3 
(CLIP3) 
-1.96 
 
Major Histocompatibility Complex Class II DQ Beta 1 
(HLA-DQB1) 
-1.37 
 
Chemokine (CXC Motif) Ligand 17 
(CXCL17) 
-1.84 
 
Lymphocyte-activation Gene 3 
(LAG3) 
-6.57 
 
Serpin Peptidase Inhibitor Clade B (ovalbumin) Member 3 
(SERPINB3) 
-1.28 
 
Peptidase Inhibitor 3 Skin-derived 
(PI3) 
-1.50 
 
Cornulin 
(CRNN) 
-2.29 
 RP4-794H19.1 6.83 
ENERGY 
METABOLISM 
Mitochondrially Encoded Cytochrome C Oxidase II 
(MT-C02) 
0.39 
 
Mitochondrially Encoded ATP Synthase 6 
(MT-ATP6) 
0.39 
 
Mitochondrially Encoded Cytochrome C Oxidase III 
(MT-C03) 
0.34 
 
Succinate Dehydrogenase Complex Subunit A 
Flavoprotein Pseudogene 3 
(SDHAP3) 
2.92 
 
Proline Dehydrogenase (oxidase) 1  
(PRODH) 
6.66 
 
Translin-associated Factor X Interacting Protein 1 
(TSNAXIP1) 
-2.37 
 
Butyrobetaine (gamma) 2-Oxoglutarate (gamma-
buyrobetaine hydroxylase) 1 
(BBOX1) 
-1.60 
STRUCTURE/ 
MATRIX 
Glycerophosphodiester Phospodiesterase Domain 
Containing 3 
(GDPD3) 
1.80 
 
 
Prostate Androgen-Regulated Mucin-like Protein 1  
(PARM1) 
 
-3.73 
 Synaptonemal Complex Protein 2  -3.53 
 50 
(SYCP2) 
 
Actin Alpha 1 Skeletal Muscle  
(ACTA1) 
-6.28 
 
Actin Alpha 1 Skeletal Muscle  
(TGM5) 
-3.81 
 
Matrix Metallopeptidase 24  
(MMP24) 
-1.67 
 
Matrix Metallopeptidase 24  
(LAMA4) 
-2.77 
 
Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 6  
(HS3ST6) 
-2.58 
 
Doublecortin-like Kinase 1 
(DCLK1) 
-6.83 
 
Collagen Type 1 Alpha 1 
(COL1A1) 
-0.41 
 
Keratinocyte Differentiation-associated Protein 
(KRTDAP) 
 
-2.80 
 
Sp8 Transcription Factor 
(SP8) 
-3.10 
CELL ADHESION/ 
CELL-CELL 
COMMUNICATION 
Protocadherin Gamma Subfamily B 2 
(PCDHGB2) 
2.93 
 
Carcinoembryonic Antigen-related Cell Adhesion 
Molecule 1 (biliary glycoprotein) 
(CEACAM5) 
-1.74 
 
G Protein-coupled Receptor 124 
(GPR124) 
-2.47 
 
Desmoglein 1 
(DSG1) 
-2.09 
 
Suprabasin 
(SBSN) 
-1.65 
 
Leucine Rich Repeat Neuronal 1 
(LRRN1) 
-2.71 
 
Cadherin 26 
(CDH26) 
-3.44 
 
Protocadherin Beta 13 
(PCDHB13) 
-4.10 
NON-CODING RNA DLGAP1-AS1 1.92 
 RP11-617F23.1 6.40 
 RP11-319G6.1 2.29 
 RP13-188A5.1 3.04 
 RP5-1057J7.6 6.39 
 ZNF32-AS2 -6.28 
 SRD5A3-AS1 -6.42 
 LINC00452 -3.84 
 CTC-523E23.1 -3.67 
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 RP11-373N22.3 -6.81 
 DLG1-AS1 -6.57 
 SOX21-AS1 -3.06 
 STK4-AS1 -6.57 
 RP1-46F2.2 -6.57 
 STXBP5-AS1 -2.35 
 HOXB-AS3 -6.69 
PSEUDOGENE RP3-342P20.2 2.73 
 
Cytochrome P450 Family 2 Subfamily B Polypeptide 7 
Pseudogene 1 
(CYP2B7P1) 
6.54 
 AC018755.16 2.21 
 
Formin Binding Protein 1 Pseudogene 1  
(FNBP1P1) 
-2.57 
 
SMAD Specific E3 Ubiquitin Protein Ligase 2 
Pseudogene 1  
(SMURF2P1) 
-2.74 
 RP11-764K9.4 -6.51 
 
Ribosomal Protein S26 Pseudogene 47 
(RPS26P47) 
-6.57 
UNCHARACTERIZED 
Ribosomal Protein SA Pseudogene 9  
(RPSAP9) 
6.43 
 AC018738.2 6.69 
 
3 Oxoacid CoA Transferase 2 Pseudogene 1  
(OXCT2P1) 
2.79 
 RP11-536C5.7 6.43 
 
Myotubularin Related Protein 9-like Pseudogene 
(MTMR9LP) 
-6.51 
 RP3-395M20.2 2.48 
 
Chromosome 8 open reading frame 56 
(C8orf47) 
3.72 
 
Polycystic Kidney Disease 1 (autosomal dominant) 
Pseudogene 5  
(PKD1P5) 
-1.43 
 
Tripartite Motif Containing 61 
(TRIM61) 
2.71 
 RP11-46H11.12 3.82 
 
Family with Sequence Similarity 186 Member B 
(FAM186B) 
3.82 
 RP11-305N23.1 6.51 
 CTC-471J1.10 6.25 
 AC006273.5 6.39 
 AC132872.2 3.76 
 RP11-247L20.4 2.43 
 
 
RP11-127120.4 
 
3.58 
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Transmembrane Protein 256 
(TMEM256) 
1.71 
 RP11-252A24.2 1.84 
 CTC-436P18.3 3.58 
 CTD-2521M24.6 6.51 
 RP11-264B17.2 2.37 
 AC012314.8 6.66 
 RP1-266L20.9 3.96 
 RP11-666A8.7 6.54 
 RP11-320L11.2 6.66 
 RP11-540A21.2 3.77 
 RP11-505K9.1 -3.53 
 AC016700.5 -6.54 
 RP11-1212A22.1 -1.68 
 
FOXD2 Antisense RNA 1  
(FOXD2) 
-6.92 
 AC018642.1 -1.84 
 AC010761.13 -6.25 
 RP11-17M16.2 -2.89 
 AC087491.2 -6.57 
 AC012313.1 -2.35 
 
Ankyrin Repeat Domain 22 
(ANKRD22) 
-1.54 
 
Ankyrin Repeat Domain 22 
(GABRP) 
-3.18 
 RP11-265B8.4 -4.53 
 AC046143.3 -2.26 
 AC025627.9 -1.82 
OTHERS/ 
MISCELLANEOUS 
Ras Protein-specific Guanine Nucleotide-releasing Factor 
1 
(RASGRF1) 
6.57 
 
Potassium Voltage-gated Channel Subfamily H (eag-
related) Member 3 
(KCNH3) 
3.35 
 
Protocadherin Alpha 3  
(PCDHA3) 
2.93 
 
Ring Finger Protein 212 
(RNF212) 
3.19 
 
Retinol Binding Protein 7 Cellular 
(RBP7) 
6.40 
 RP1-90J20.12 6.54 
 
ATPase Ca++ Transporting Cardiac Muscle Fast Twitch 1 
(ATP2A1) 
3.77 
 
 
DNAJ (Hsp40) Homolog Subfamily C Member 12 
(DNAJC12) 
 
-3.81 
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GLIS Family Zinc Finger 2 
(GLIS2) 
 
-1.45 
 
GLIS Family Zinc Finger 2 
(HIST1H2AI) 
-3.63 
 
Cysteine-rich Secretory Protein 3 
(CRISP3) 
-3.05 
 
Myelin Regulatory Factor 
(MYRF) 
-6.54 
 
Calcyphosine 2 
(CAPS2) 
-2.97 
 
Calcyphosine 2 
(SLC34A2) 
-1.79 
 
Microseminoprotein Beta 
(MSMB) 
-2.92 
 
Kallikrein-related Peptidase 14 
(KLK14) 
-3.76 
 
Cytochrome P450 Family 4 Subfamily F Polypeptide 3 
(CYP4F3) 
-3.90 
 P3-410C9.1 -3.82 
 
Cytochrome P450 Family 4 Subfamily F Polypeptide 22 
(CYP4F22) 
-1.71 
 
Discs Large (Drosophila) Homolog-associated Protein 3  
(DLGAP3) 
-6.42 
 
HOP Homeobox 
(HOPX) 
-1.32 
 
Phospholipase A2 Gropu IVE 
(PLA2G4E) 
-2.51 
 
Aldehyde Dehydrogenase 3 Fmaily Member B2 
(ALDH3B2) 
-1.44 
 
Calmodulin-like 5 
(CALML5) 
-1.31 
 
Fetuin B 
(FETUB) 
-2.53 
 
Zinc Finger Protein 750  
(ZNF750) 
-1.26 
 
Phospholipase A2 Group VII (platelet-activating factor 
acetylhydrolase plasma)  
(PLA2G7) 
-2.09 
 
CDKN2B-Antisense RNA 1 
(CDKN2B-AS1) 
-6.25 
 
Small Integral Membrane Protein 6 
(SMIM6) 
-3.71 
 
Rho Guanine Nucleotide Exchange Factor (GEF) 33 
(ARHGEF33) 
-3.71 
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Relaxin 2  
(RLN2) 
-6.57 
 
Hephaestin 
(HEPH) 
-3.71 
 AC012314.8 0.03 
 AC018766.5 0.08 
 
BTB_(POZ) 
(BTBD16 
0.09 
 
Lin-37 homolog 
(LIN37) 
0.08 
 
Mucin 12 Cell Surface Associated 
(MUC12) 
0.06 
 RP11-265B8.4 -0.09 
 RP11-336A10.4 0.02 
 RP11-536C5.7 0.08 
 RP11-552M11.4 0.03 
 RP11-767N6.7 0.14 
 RP11-867G23.3 -0.01 
 
 
 
 
Table 2. Transcriptomic profile of vascular endothelial growth factor (VEGF)-induced 
proliferative signature genes in Human cervical epithelial cells. Only the gene expression of 
the first six genes in the Table were significantly altered. 
GENE 
NC READ 
COUNT 
VEGF50 READ 
COUNT 
FOLD 
CHANGE 
P-ADJ 
VALUE UP/DOWN 
1. SESN3 1725.83 1171.06 -0.42 0.008 Down 
2. CXCL14 2852.78 1858.32 -0.42 0.024 Down 
3. SLC6A  708.78 401.75 -0.44 0.025 Down 
4. MALAT1 5246.02 6927.50 0.33 0.025 Up 
5. FAU 2578.77 3485.36 0.35 0.031 Up 
6. NEDD8 631.45 846.48 0.33 0.099 Up 
7. MYB 6.07 15.62 0.09 NA Up 
8. FNTB 3.77 8.48 0.05 NA Up 
9. RSPO4 1.38 4.74 0.04 NA Up 
10. HERC2P10 11.27 14.86 0.03 NA Up 
11. CSNK2B 63.29 105.16 0.22 NA Up 
12. APOBEC3A 2.11 3.39 0.01 NA Up 
13. CLEC3A 7.32 1.33 0.06 NA Up 
14. STRADA 31.25 17.40 -0.13 NA Down 
15. ANKRD44 9.30 5.39 -0.04 NA Down 
16. TMPRSS13 62.74 37.78 -0.12 NA Down 
17. SDR9C7 25.78 15.16 -0.06 NA Down 
18. TP53TG5 16.25 9.42 -0.07 NA Down 
19. SOSTDC1 13.29 8.45 -0.05 NA Down 
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